Literature DB >> 35764745

Charting roadmaps towards novel and safe synergistic immunotherapy combinations.

Miguel F Sanmamed1,2,3,4, Pedro Berraondo1,2,4, Maria E Rodriguez-Ruiz1,2,3, Ignacio Melero5,6,7,8.   

Abstract

Checkpoint inhibitor-based cancer immunotherapy is often combined in the clinic with other immunotherapy strategies, targeted therapies, chemotherapy or standard-of-care treatments to achieve superior therapeutic efficacy. The large number of immunotherapy combinations that are currently undergoing clinical testing necessitate the establishment of faithful criteria to prioritize optimal combinations with evidence of synergy, to determine their safety and optimal sequence of administration and to identify biomarkers of therapy resistance and response. In this review, we focus on recent developments in immunotherapy combinations and reflect on how combinations should be optimized to maximize the impact of immunotherapy in clinical oncology.
© 2022. Springer Nature America, Inc.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35764745     DOI： 10.1038/s43018-022-00401-1

Source DB:  PubMed          Journal:  Nat Cancer        ISSN： 2662-1347


  224 in total

1.  Combination chemotherapy in the treatment of advanced Hodgkin's disease.

Authors:  V T Devita; A A Serpick; P P Carbone
Journal:  Ann Intern Med       Date:  1970-12       Impact factor: 25.391

Review 2.  Tuberculosis.

Authors:  Stephen D Lawn; Alimuddin I Zumla
Journal:  Lancet       Date:  2011-03-21       Impact factor: 79.321

Review 3.  Evolving synergistic combinations of targeted immunotherapies to combat cancer.

Authors:  Ignacio Melero; David M Berman; M Angela Aznar; Alan J Korman; José Luis Pérez Gracia; John Haanen
Journal:  Nat Rev Cancer       Date:  2015-08       Impact factor: 60.716

4.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.

Authors:  Roy M Gulick; Heather J Ribaudo; Cecilia M Shikuma; Stephanie Lustgarten; Kathleen E Squires; William A Meyer; Edward P Acosta; Bruce R Schackman; Christopher D Pilcher; Robert L Murphy; William E Maher; Mallory D Witt; Richard C Reichman; Sally Snyder; Karin L Klingman; Daniel R Kuritzkes
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

Review 7.  Combination cancer immunotherapy and new immunomodulatory targets.

Authors:  Kathleen M Mahoney; Paul D Rennert; Gordon J Freeman
Journal:  Nat Rev Drug Discov       Date:  2015-08       Impact factor: 84.694

Review 8.  The Next Decade of Immune Checkpoint Therapy.

Authors:  Padmanee Sharma; Bilal A Siddiqui; Swetha Anandhan; Shalini S Yadav; Sumit K Subudhi; Jianjun Gao; Sangeeta Goswami; James P Allison
Journal:  Cancer Discov       Date:  2021-04       Impact factor: 39.397

9.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.

Authors:  Giao Q Phan; James C Yang; Richard M Sherry; Patrick Hwu; Suzanne L Topalian; Douglas J Schwartzentruber; Nicholas P Restifo; Leah R Haworth; Claudia A Seipp; Linda J Freezer; Kathleen E Morton; Sharon A Mavroukakis; Paul H Duray; Seth M Steinberg; James P Allison; Thomas A Davis; Steven A Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-25       Impact factor: 12.779

Review 10.  Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium.

Authors:  Luca Falzone; Salvatore Salomone; Massimo Libra
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.